Skip to main content
. 2017 Jul 27;8(56):95116–95134. doi: 10.18632/oncotarget.19618

Figure 3. Abemaciclib is more effective against RCC cell lines in combination with sunitinib.

Figure 3

786-O (A) and Caki-1 (B) cells were treated with single agent therapy, or in combination with sunitinib. Cellular viability was determined by CellTiter-Glo®.